

Ready to start planning your care? Call us at [800-525-2225](tel:800-525-2225) to make an appointment.

×



Memorial Sloan Kettering  
Cancer Center

[Make an Appointment](#)

[Back](#)

[About Us](#)

[Tangible Materials Available for Licensing](#)

[Learn About Cancer & Treatment](#)

## ABOUT US

[Our mission, vision & core values](#)

[Leadership](#)

[History](#)

[Inclusion & belonging](#)

[Annual report](#)

[Give to MSK](#)

## FOR THE MEDIA

of Caov-3 ovarian carcinoma cells *in vitro*. These cells express the NB/70K, CA-125, Ba-2, and Ca-1 tumor-associated antigens. The Caov-3 cells harbor a nonsense mutation in the *p53* gene, and have multiple copies of the ovarian cancer oncogene *PIK3CA*. They are sensitive to vinblastine, cisplatin, and adriamycin. These cells fail to grow in soft agar but are tumorigenic when injected into immunocompromised mice.

## Source

This cell line was established from the primary tumor of a 54-year-old Caucasian female with adenocarcinoma of the ovary.

## Inventors

Jorgen Fogh, PhD, formerly at Sloan Kettering Institute, Memorial Sloan Kettering

## Key References

- Buick RN et al. (1985) Comparative properties of five human ovarian adenocarcinoma cell lines. *Cancer Research* 45: 3668-3676 (PubMed ID: [4016745](#) )
- Yaginuma Y et al. (1992) Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. *Cancer Research* 52: 4196-4199 (PubMed ID: [1638534](#) )
- Shayesteh L et al. (1999) PIK3CA is implicated as an oncogene in ovarian cancer. *Nature Genetics* 21: 99 - 102 (PubMed ID: [9916799](#) )

## Licensing Information

This cell line may be licensed nonexclusively for research or commercial purposes.

- Express License: For internal research purposes by a for-profit entity: 1) Fill out MSK's ATCC Express License, see [here](#) for links to the online fillable ATCC Express License, as well as a PDF version. 2) After execution by MSK, you will receive a signed copy, and can then place your order with ATCC. For detailed guidance on how to fill out this webform, see [here](#) . Please note: In order to streamline and expedite the licensing of select MSK cell lines, the terms of this non-exclusive license are non-negotiable. This license is only available for select cell lines, including this one. Once this license has been executed by MSK, you will receive a signed copy and payment instructions; all payments up to \$10,000 must be made by credit card.
- Commercial License: Contact MSK's Tangible Materials team at [TRMOTDRTM@mskcc.org](mailto:TRMOTDRTM@mskcc.org) .

For non-licensing requests from academic-research institutions : Contact Frances Weis-Garcia, PhD, Associate Laboratory Member/Head, Antibody & Bioresource Core Facility, MSK, [646-888-2354](tel:646-888-2354) , [weisgarf@mskcc.org](mailto:weisgarf@mskcc.org) .

## Stage of Development

Ready to use

## Indications

[Cancer](#) › [Ovarian](#)

## Types

[Research Tools](#) › [Cell Lines](#)

© 2026 Memorial Sloan Kettering Cancer Center